Pfizer plans to close its neuroscience discovery and early development programs, the latest large drug maker to turn its corporate back on developing drugs for central nervous system disorders. As a result, about 300 jobs are being eliminated from three different Pfizer locations — Cambridge and Andover, Mass., and Groton, Conn.
The programs were primarily focused on Alzheimer’s and Parkinson’s disease, according to a Pfizer spokesman. As of Oct. 31, a Pfizer web page that is no longer visible listed nine neuroscience projects under way — six that were in Phase 1, two more in Phase 2, and another in Phase 3.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
